PMID-38847460 – Survodutide Phase 2 MASH and Fibrosis Trial
Sanyal AJ, Bedossa P, Engel Mayer S, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38847460 |
| DOI | 10.1056/NEJMoa2401755 |
| Year | 2024 |
| Journal | New England Journal of Medicine |
| Study Type | RCT (Phase 2) |
| Evidence Level | II |
| Sample | n=293 adults with biopsy-confirmed MASH and fibrosis (F1-F3) |
| Peptide(s) Studied | Survodutide |
Key Findings
- MASH improvement without worsening fibrosis: 47% (2.4 mg), 62% (4.8 mg), 43% (6.0 mg) vs. 14% (placebo)
- All survodutide doses were significantly superior to placebo for the primary endpoint (P<0.001 for 4.8 mg)
- Fibrosis improvement by >=1 stage: 34% (2.4 mg), 36% (4.8 mg), 34% (6.0 mg) vs. 22% (placebo)
- Significant reductions in liver fat content measured by MRI-PDFF
- Improvements in liver enzyme levels (ALT, AST) across dose groups
- Body weight reductions of approximately 6-11% accompanied the hepatic improvements
- The 4.8 mg dose showed the best benefit-risk balance
- The 6.0 mg dose did not show better efficacy than 4.8 mg, possibly due to higher GI-related discontinuation
Study Design
Phase 2, randomised, double-blind, placebo-controlled trial. Adults with biopsy-confirmed MASH and fibrosis stages F1-F3 were randomized 1:1:1:1 to survodutide 2.4 mg, 4.8 mg, 6.0 mg, or placebo once weekly for 48 weeks. The trial included a 24-week rapid-dose-escalation phase followed by a 24-week maintenance phase. Primary endpoint was histological improvement in MASH without worsening of fibrosis at 48 weeks, assessed by central pathology review.
Limitations
- Phase 2 trial with limited sample size (n=293)
- Biopsy-based endpoints have inherent sampling variability
- 48-week duration may not capture long-term hepatic remodeling
- High GI adverse event rate, especially at 6.0 mg dose
- No active comparator (e.g., resmetirom or tirzepatide for MASH)
Clinical Relevance
This NEJM publication established survodutide as a first-in-class dual GLP-1/glucagon agonist with demonstrated MASH resolution efficacy. The glucagon receptor component is mechanistically important for liver disease: glucagon promotes hepatic fatty acid oxidation and ketogenesis, directly addressing hepatic lipid accumulation. The 62% MASH resolution rate at 4.8 mg is competitive with tirzepatide's MASH data. This positions survodutide uniquely for patients with both obesity and MASH/NAFLD — conditions that frequently coexist. Phase 3 trials are ongoing.
Related
#research #RCT #evidence-level-II #metabolic #survodutide #investigational #gastrointestinal